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Abstract
Objective—This study is an examination of sleep, pain, depression, and physical functioning at
baseline and 1-year followup among patients with fibromyalgia syndrome (FMS). Although it is
clear that these symptoms are prevalent among FMS patients and that they are related, the
direction of the relationship is unclear. We sought to identify and report sleep problems in this
population and to examine their relationship to pain, depression, and physical functioning.
Methods—Patients diagnosed with fibromyalgia were recruited from a Southern California
health maintenance organization and evaluated according to American College of Rheumatology
criteria in the research laboratory. Six hundred patients completed the baseline assessment and 492
completed the 1-year assessment. Measures included the Center for Epidemiologic Studies
Depression Scale, the McGill Pain Questionnaire, the Pittsburgh Sleep Quality Index, and the
Fibromyalgia Impact Questionnaire.
Results—The majority of the sample (96% at baseline and 94.7% at 1 year) scored within the
range of problem sleepers. Path analyses examined the impact of baseline values on 1-year values
for each of the 4 variables. No variable of interest predicted sleep, sleep predicted pain (β = 0.13),
pain predicted physical functioning (β = −0.13), and physical functioning predicted depression (β
= −0.10).
Conclusion—These findings highlight the high prevalence of sleep problems in this population
and suggest that they play a critical role in exacerbating FMS symptoms. Furthermore, they
support limited existing findings that sleep predicts subsequent pain in this population, but also
extend the literature, suggesting that sleep may be related to depression through pain and physical
functioning.
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INTRODUCTION
Fibromyalgia syndrome (FMS) is a chronic musculoskeletal pain disorder. Although pain is
the primary chronic symptom, disturbed sleep is also a major symptom of patients with
FMS. Patients report difficulty falling asleep, significantly more nighttime awakenings, and
unrefreshing sleep (1). The majority of sleep research in patients with FMS focuses on the
quality of sleep, because the amount of sleep does not appear to differ between FMS patients
and healthy subjects (2). Analysis of electroencephalograms indicates that patients with
FMS take longer to fall asleep and have frequent arousals, extended stage 1 sleep, and little
slow wave sleep (1), which may indicate a vigilant arousal state during sleep (3).
Furthermore, when depressed, patients with FMS report lower levels of activity and
increased sleeping during the day, and significantly more sleep interruptions and movement
at night (4).
Sleep problems have been related to both depression and pain among patients with FMS in
numerous studies (3); however, the direction of these relationships is not yet well
established. The Neuromatrix Theory of Pain (5) suggests that pain is impacted by
multidimensional factors, including psychological and general health characteristics of
individuals. Sleep problems, which fit into the general health characteristics construct of the
theory, may impact the neuromatrix through their negative effects on other systems, such as
the immune system. Support for this theory comes from research suggesting that sleep may
impact the neuromatrix through its effects on intervening systems. For example, lack of
sleep leaves individuals more susceptible to infection (6), elevated resting blood pressure
and decreased muscle sympathetic nerve activity (7), and increased activity of the autonomic
nervous system (8). Specific to FMS, research suggests that good sleep quality may
moderate the relationship between affect and pain (9). Essentially, a good night’s sleep
increases our ability to resist bouts of pain; poor sleep, on the other hand, especially when
chronic, may increase our vulnerability to symptoms.
Nicassio and Wallston (10) evaluated the relationship between sleep problems, pain, and
depression over 2 years among patients with rheumatoid arthritis. Their longitudinal
analyses indicated that sleep problems did not predict subsequent pain, but pain predicted
subsequent sleep problems. In addition, sleep problems did not predict subsequent
depression, but pain did.
Affleck et al (11) investigated the temporal sequence of pain and sleep problems among a
sample of patients with FMS over a 30-day period, using handheld devices to record sleep
quality in the morning and pain throughout the day. Their findings suggested that sleep
difficulties the night before predicted increased pain during the day, but daily measures of
pain did not predict poorer subsequent sleep.
The difference in findings between Affleck et al (11) and Nicassio and Wallston (10) may
have occurred because they studied different patient populations. Sleep may very well be an
etiologic factor for FMS symptoms, but not for symptoms in other rheumatic conditions.
This was investigated by Moldofsky and Scarisbrick (12), who altered the sleep pattern of 6
healthy subjects to imitate those of FMS patients. All subjects subsequently reported
symptoms similar to those reported by patients with FMS. Their study suggested that poor
sleep may have a significant effect on the development or exacerbation of FMS symptoms
and paved the way for future studies of sleep in patients with FMS.
In the present study, we examined sleep, pain, depression, and physical functioning at
baseline and 1 year later among patients with FMS. Because they used a similar research
design, we built on the work of Nicassio and Wallston (10) by using a path analysis
approach; however, because our sample consisted of FMS patients, we hypothesized that our
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findings would match those of Affleck and colleagues (11), in that baseline sleep would
predict subsequent pain. We also predicted that both sleep and pain would predict
subsequent depression. We had no specific prediction for physical functioning because this
variable has not been examined in relation to sleep in the literature.
PARTICIPANTS AND METHODS
Participants
The participants consisted of 600 members of a large health maintenance organization
(HMO). They were largely women (95.3%) and white (85%), with a mean ± SD age of
53.92 ± 11.45 years. Most participants were married (64.2%) and almost half were
employed (49.5%). Their average family income was between $30,000 and $50,000, and
81% of the sample reported at least some college education. Participants reported
experiencing FMS symptoms for a mean ± SD of 13.8 ± 13.2 years.
Measures
Demographic characteristics—Participants reported their age (in years), highest level
of education completed, work status (employed/not employed), ethnicity (white/ethnic
minority), and family income.
Sleep quality—The Pittsburgh Sleep Quality Index (PSQI) (13) estimates sleep duration,
sleep latency, and the frequency and severity of specific sleep-related problems during the
past month. The index comprises 19 items grouped into 7 component scores, each weighted
equally on a 4-point Likert scale, ranging from 0 (not during the past month) to 3 (≥3 times a
week). The component scores are summed to yield a global PSQI score. This score ranges
from 0–21, with higher scores indicating worse quality of sleep. Reliability estimates
showed internal consistency of 0.83 for the 7 component scores, and test–retest reliability of
0.85 for the PSQI global scores (13).
Pain assessment—To assess pain we used the Pain Rating Index scale of the McGill
Pain Questionnaire (14), which assesses the sensory qualities and cognitive affective
characteristics of pain perception. It comprises 78 adjectives divided into 4 subscales:
sensory, affective, evaluative pain, and miscellaneous pain. Adjectives are presented in
groups of 3–6 and the respondent is instructed to mark the word that best describes his or her
pain in the past week. Scores ranged from 0 (mild) to 6 (severe). Mean scale values are
obtained from each category and then averaged to yield 1 score (14). Test–retest reliability
has been demonstrated previously (r = 0.70) (14). Construct validity for the 3 pain
dimensions has also been demonstrated (15).
Depression—The Center for Epidemiologic Studies Depression Scale (CES-D) (16)
contains 20 items rated on a 4-point Likert scale ranging from 0 (rarely or none of the time)
to 3 (most or all of the time), and measures symptoms during the past week. The scale is
reliable (r = 0.88), internally consistent (alpha coefficients range from 0.80–0.90), has
moderate test–retest reliability (r = 0.40 and greater), and high concurrent and construct
validity (16).
Physical functioning score—The Fibromyalgia Impact Questionnaire (FIQ) is a brief,
self-administered, 10-item questionnaire that measures physical functioning, depression,
work status, sleep, anxiety, pain, stiffness, fatigue, and well-being over the past week in
patients with FMS (17). The first item of the FIQ consists of 10 subitems that focus
primarily on the patient’s ability to perform large muscle tasks (i.e., doing yard work,
vacuuming a rug), presented in a Likert-scale–type format ranging from 0 (always able to
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do) to 3 (never able to do). The sum of these 10 subitems is divided by the number of valid
scores to provide 1 physical functioning score, which for the purposes of these analyses
were recoded so that higher scores reflected better functioning. The scale has previously
demonstrated test–retest reliability (0.56–0.95). Both content and construct validity were
demonstrated in the development of the scale (17).
Procedure
Participants were part of a larger study measuring the effects of social support and education
on health status, health care utilization, and quality of life in patients with FMS (18).
Recruitment was carried out through newspaper advertisements, mass mailings to HMO
members, flyers in physicians’ offices, and physician referrals. When asked how a
participant heard about the study, most reported multiple modalities, making comparisons
between patients recruited by the different methods impossible. To be eligible, participants
had to be diagnosed by a physician and had to meet American College of Rheumatology
criteria for fibromyalgia (19). A trained examiner performed the manual tender point
examination after informed consent was obtained. Only participants who met all criteria
were retained for this study.
Informed written consent was obtained from all volunteers. The assessments lasted ~1 hour.
Participants completed a battery of questionnaires at the baseline assessment and again 1
year later. After the baseline assessment, subjects were randomly assigned to 1 of 2
interventions (social support or social support and education) or to a no treatment control
group. The contents of the educational sessions and the social support tasks were
standardized and adapted specifically for FMS. There were no differential changes in health
status or psychosocial measures used in the present study by groups, although the social
support and education group was less helpless at the 1-year assessment than the other groups
(18). Therefore, we collapsed the groups for the present study.
RESULTS
Completers versus noncompleters
Of the 600 participants who joined the study, 492 (82%) completed the 1-year assessment.
We examined differences between these and the 108 participants who dropped out of the
study. There were no significant differences between the participants who continued and
those who dropped out in any of the demographic variables (P > 0.05), or in sleep, pain,
depression, or physical functioning (P > 0.05).
Descriptive analyses
Sleep—Participants scored high on the PSQI at both time points, but significantly higher at
baseline than at 1 year (baseline mean ± SD 11.22 ± 3.96, 1-year mean ± SD 10.75 ± 4.11;
F[1,490] = 7.8, P = 0.006). Scores of ≥5 on the PSQI indicated bad sleepers (20). Only 4%
of the sample scored <5 at baseline, and 5.3% scored <5 at the 1-year assessment,
suggesting significant presence of poor sleep quality in this sample at both assessments. The
PSQI has 7 component scores that measure various aspects of sleep. Table 1 shows detailed
information on the sleep quality of participants at baseline and 1 year. In general, for each of
the component scores, participants reported more improvement, i.e., scored lower, at 1 year
than at baseline, with statistically significantly less severe sleep problems at 1 year on all
domains except for daytime dysfunction and use of sleep medication. Although daytime
dysfunction did not change, use of sleep medication increased significantly from the
baseline assessment to the 1-year assessment.
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Pain—The Pain Rating Index scale of the McGill Pain Questionnaire showed a small but
significant reduction in pain at 1 year compared with baseline (baseline mean ± SD 1.68 ±
0.68, 1-year mean ± SD 1.45 ± 0.68; F[2,460] = 20.67, P < 0.001). Given the range from 0–
6 with 6 indicating severe pain, participants reported relatively low levels of pain throughout
the study. In previous research of patients with FMS, mean ± SD PSQI scores ranged from
2.1 ± 0.3 to 2.3 ± 0.08 (21,22).
Depression scores—At baseline, participants scored in the depressed range, according to
the CES-D cutoff score of 19 suggested for populations with FMS pain (mean ± SD 19.79 ±
11.53) (23), with 49.7% of the sample at or above this cutoff score. At the 1-year followup,
mean CES-D scores were below the cutoff (mean ± SD 14.78 ± 9.68), with 30.5% of
participants scoring ≥19. The difference was statistically significant (F[1,491] = 115.4, P <
0.001).
Physical functioning—At baseline, participants scored a mean ± SD of 1.64 ± 0.71 on a
0–3-point scale, where higher scores indicated better functioning; at 1 year it was 1.71 ±
0.70. These scores were not statistically significantly different, suggesting consistency
across the 2 time periods in participants’ abilities to carry out basic household tasks such as
shopping, vacuuming, and yard work.
Correlational analyses
Table 2 shows the correlations among all variables in the study. For the main study variables
(sleep, pain, physical functioning, and depression), baseline and 1-year data are shown.
Younger women fared better on all symptoms over time, except for 1-year pain and 1-year
depression, which did not correlate with age. Income had small correlations with all
variables except for 1-year sleep. Other noteworthy correlations are those between sleep and
ethnicity: whites tended to report better sleep than nonwhites, and education correlated with
the 3 main variables, with higher education associated with better outcome overall.
Longitudinal prediction analyses
Building on the work of Nicassio and Wallston (10), we conducted a path analysis to
examine hypothesized causal relationships among pain, sleep, physical functioning, and
depression at baseline and 1 year. The analysis was conducted using LISREL 8.8 (24),
which tests theoretical causal models based on the observed pattern of relationships (e.g.,
correlations) among a set of measured variables. This type of path analysis offers several
advantages over traditional regression equation analysis, including more accurate regression
estimates, reduced likelihood of spurious findings, and the ability to handle missing data.
Moreover, the hypothesized causal model can be evaluated based on how closely it matches
the observed pattern of relationships among measured variables. Two goodness-of-fit
statistics were used to evaluate the causal model in this study: the chi-square statistic and the
root mean square error of approximation (RMSEA) (25). The chi-square statistic measures
the absolute fit between the hypothesized model and the observed pattern of relationships
among measured variables. A nonsignificant chi-square statistic suggests there is no
difference between the hypothesized and observed patterns of relationships and therefore,
the hypothesized model is acceptable. The RMSEA statistic adjusts the measure of absolute
fit based on the complexity of the hypothesized model, with more complex models receiving
a penalty. Smaller values of RMSEA indicate better model fit, with values <0.06
representing acceptable model fit (26).
All baseline measures were modeled as predictors and all of the 1-year measures were
modeled as dependent variables. In addition, the following demographic and disease
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variables showed significant zero-order correlations with the dependent variables and were
included in the path model as predictors: age, ethnicity (0 = white, 1 = nonwhite), level of
education, income, marital status (0 = not married, 1 = married), work status (0 = not
working, 1 = working), and length of time with FMS symptoms. The data from all study
participants (n = 600) were included, and missing values were handled using full
information maximum likelihood, which is superior to traditional methods of handling
missing data (e.g., listwise or pairwise deletion) (27).
Regression equation paths from all predictors to all dependent variables were estimated. In
addition, the correlations among all predictor variables were estimated as well as the
correlations among all dependent variables. The resulting path model is shown in Figure 1.
For the sake of clarity, only significant regression equation paths (P < 0.05) are shown. Age,
ethnicity, income, and marital status were included in the model, but did not significantly
predict any of the dependent variables; therefore, they are not shown in the figure.
As the figure shows, both baseline sleep quality (β = 0.49) and education (β = −0.10) were
significant predictors of 1-year sleep quality, accounting for 35% of the variance. More
education predicted better sleep quality.
Baseline pain (β = 0.31) and sleep quality (β = 0.13) were significant predictors for pain at 1
year, along with the length of time since FMS symptoms began (β = 0.09). These 3
predictors accounted for 22% of the variance in pain at 1 year. Greater sleep disturbance at
baseline in addition to more time since the onset of FMS symptoms predicted greater pain at
1 year.
Physical functioning at 1 year was predicted by baseline physical functioning (β = 0.38) and
pain (β = −0.13), accounting for 27% of the variance. Greater pain at baseline predicted less
physical functioning at 1 year. Finally, depression at 1 year was predicted by baseline
depression (β = 0.45), baseline physical functioning (β = −0.10), and work status (β =
−0.08), accounting for 31% of the variance in 1-year depression. Greater baseline physical
functioning and being employed predicted less depression at 1 year.
The hypothesized model showed close fit to the data (χ2[11, n = 600] = 13.42, P = 0.27,
RMSEA = 0.019). This model suggests a specific causal sequence involving sleep, pain,
physical functioning, and depression among patients with FMS. Specifically, greater sleep
disturbance predicts greater pain, which then predicts poorer physical functioning. Poorer
physical functioning in turn predicts greater depression.
Because the item on the PSQI that measures use of sleep medication showed an increase
from the baseline assessment to the 1-year assessment (see Table 2), we ran longitudinal
prediction analyses with this 1-item variable removed from the measure and included it as a
covariate. There were no changes to the model as a whole, with minimal and not significant
changes to the coefficients.
DISCUSSION
As hypothesized, our findings agree with those of Affleck et al (11), in that sleep precedes
pain in fibromyalgia, even with different methodologies and time measures. Whereas
Affleck et al (11), using ecological momentary assessment over a 1-week period, found that
sleep predicted pain in patients with FMS, the present study, using traditional self-report
measures of pain at 2 points during a 1-year period, reached the same conclusion.
This longitudinal study suggests a causal sequence of symptom impact. Specifically, in the
present model no baseline variable predicted 1-year sleep, baseline sleep predicted 1-year
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pain, baseline pain predicted 1-year physical functioning, and baseline physical functioning
predicted 1-year depression. Clearly, sleep problems among patients with FMS impact
symptoms in the long term and deserve more attention both in research and in clinical
practice, because they seem to initiate a cascade of symptoms that lead to depression, a
serious and prevalent problem in this population. The importance of sleep in the
symptomatology of FMS has been identified by sleep researchers as well (2). However, the
present study measured these variables over 2 time periods, measuring baseline predictors of
1-year outcomes instead of various and continuous time periods. Therefore, it is not clear
whether these findings truly reflect what would be seen over time if these participants were
followed for longer periods and measured repeatedly.
Only 1 previous study with a small sample size (n = 16) has reported detailed information on
the sleep quality of patients with FMS (28). Our larger sample provides greater support for
generalizing findings regarding the characteristics and effects of sleep quality among
patients with FMS. Although sleep quality was significantly better at the 1-year assessment,
it remained poor, indicating poor sleep may be a chronic problem, with dysfunction during
the day showing no improvement. This is further supported by literature indicating that,
despite receiving 6–8 hours of sleep, patients with FMS wake up stiff, fatigued, and in pain
(29). This suggests that improving sleep quality in this population would decrease pain,
possibly also impacting functioning and depression, and that the focus should be on quality
of sleep, not quantity.
For depression, pain, and sleep, patients improved by the 1-year assessment. We considered
whether these improvements were related to the intervention. The intervention consisted of a
social support group, a social support and education about FMS group, and a no treatment
control group. However, the intervention groups did not differ from the control group in any
of these variables, i.e., the changes in symptoms occurred in the presence of, but not because
of, the intervention. Although these findings could represent a simple regression to the mean
and should be examined in further research, our findings are consistent with those of other
studies indicating that, although FMS symptoms may decrease in severity (30), patients still
score within clinical ranges across time (1,31).
These conclusions do not hold as strongly for depression in this sample. The improvements
in depression at followup were noteworthy, both as overall means and as proportions that
scored above and below the clinical cutoff. Although almost 50% of participants scored at
the depressed range at baseline, that percentage dropped to 30.5% at 1 year. Although the
rates remained high, this drop is both statistically and clinically significant. It could be that
there was a placebo effect, because all participants were in a research study. Also
noteworthy was the role of depression in the path model; specifically, baseline depression
did not contribute to pain, physical functioning, or sleep at 1 year. Our findings suggest that
depression may be the end result of a process that begins with sleep problems.
Interestingly, physical functioning did not change from baseline to the 1-year assessment as
the other variables did. Scores were consistently average (~1.7 out of a 4-point scale) at
baseline and 1 year. Furthermore, only baseline pain predicted physical functioning at the 1-
year assessment, with a very small effect size. Physical functioning did predict depression in
this sample. This finding was not surprising, although it was not hypothesized. Research has
suggested for some time that physical disability predicts later depression (32). The model of
depression by Lewinsohn et al (33) suggests that circumstances that disrupt adaptive
functioning increase vulnerability to depression. For instance, the individual may be more
susceptible to depression as a result of not being able to engage in valued activities such as
self-care.
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When interpreting these results, it is important to keep in mind that our sample was highly
educated and mostly white. Therefore, generalizing these findings to other populations
entails some risks. Also, this sample reported elevated levels of sleep disturbance.
Therefore, it would be difficult to determine whether similar results would be elicited in a
sample with varying levels of sleep quality. The present study used self-report measures to
assess depression, pain, and sleep. These measures may not reflect the symptoms as
accurately as objective measures, although subjective reports of sleep quality have been
corroborated with objective data for this population (34). Future studies would benefit from
including objective measures of these variables. Some studies have used electronic sleep
diaries (9,11) or actigraphy (2,34) to study FMS pain and sleep. However, this methodology
becomes more difficult when studying larger samples over a longer period of time. Also, all
measures assessed symptoms over the past week except for the sleep measure, which
assessed symptoms over the past month. This difference in measurement may result in
discrepancies, because symptoms may have been very different over the past month and in
the past week. However, the correlations between sleep and other variables were similar to
those among other indices of symptoms. Finally, all findings should be interpreted with
caution, given the long time frame between both assessments. It is possible that there were
fluctuations in each variable that were not captured by the 2 assessment periods, instead of a
gradual increase or decline suggested by the data. Future studies should attempt more
frequent assessments to gain a better understanding of the course of these problems.
Alternately, a strength of the present study was the large sample that was followed over
time. Our design allowed us to include more variables than smaller studies because the latter
have lower power. Therefore, the present study was able to determine the impact of the main
study variables in the presence of relevant demographic and disease variables. In conclusion,
the present study highlights the importance of further research in sleep among this patient
population, given the findings of the path model.
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Figure 1.
Path model of sleep, pain, physical functioning, and depression. Italicized coefficients are
error terms, representing the proportion of variation in the variable not accounted for by the
model; P < 0.05 for all coefficients. PSQI = Pittsburgh Sleep Quality Index; FMS =
fibromyalgia syndrome; PRI = Pain Rating Index; Function = physical functioning; CES-D
= Center for Epidemiologic Studies Depression Scale.
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Table 1
Pittsburgh Sleep Quality Index sleep component scores at baseline and 1 year
Component
Baseline,
mean ± SD
1 year,
mean ± SD F statistic P
Sleep quality, 0 = very good to 3 = very bad 1.66 ± 0.80 1.52 ± 0.79 F(1,488) = 13.39 <0.001
Sleep latency (time to fall asleep), 0 = <15 minutes to 3 = >60 minutes 1.55 ± 1.05 1.44 ± 1.12 F(1,490) = 6.58 0.011
Sleep duration (hours of sleep), 0 = >7 hours to 3 = <5 hours 1.34 ± 0.93 1.21 ± 0.90 F(1,490) = 11.00 0.001
Sleep efficiency (percentage of time asleep while in bed), 0 = >84% to 3 = <65% 1.41 ± 1.23 1.09 ± 1.26 F(1,490) = 25.81 <0.001
Sleep disturbances, 0 = not during the past month to 3 = ≥3 times/week 1.89 ± 0.63 1.73 ± 0.66 F(1,490) = 20.87 <0.001
Use of sleep medication, 0 = not during the past month to 3 = ≥3 times/week 1.78 ± 1.37 1.97 ± 1.13 F(1,488) = 9.04 0.003
Daytime dysfunction, 0 = not during the past month to 3 = ≥3 times/week 1.61 ± 0.79 1.55 ± 0.82 F(1,489) = 2.49 0.115
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